KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Deffered Revenue: 2010-2011

Historic Non-Current Deffered Revenue for Biomarin Pharmaceutical (BMRN) over the last 2 years, with Dec 2011 value amounting to $8.8 million.

  • Biomarin Pharmaceutical's Non-Current Deffered Revenue rose 62.15% to $13.1 million in Q3 2012 from the same period last year, while for Sep 2012 it was $13.1 million, marking a year-over-year increase of 62.15%. This contributed to the annual value of $8.8 million for FY2011, which is 68.19% up from last year.
  • Biomarin Pharmaceutical's Non-Current Deffered Revenue amounted to $8.8 million in FY2011, which was up 68.19% from $5.2 million recorded in FY2010.
  • In the past 5 years, Biomarin Pharmaceutical's Non-Current Deffered Revenue ranged from a high of $8.8 million in FY2011 and a low of $5.2 million during FY2010.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $7.0 million (2010), whereas its average is $7.0 million.
  • Data for Biomarin Pharmaceutical's Non-Current Deffered Revenue shows a peak YoY spiked of 68.19% (in 2011) over the last 5 years.
  • Biomarin Pharmaceutical's Non-Current Deffered Revenue (Yearly) stood at $5.2 million in 2010, then spiked by 68.19% to $8.8 million in 2011.